# US 10,766,961 B2 · Anti-VEGFR2 antibody therapy for hepatocellular carcinoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,766,961 B2
- Document ID: US10766961B2
- Status: Granted
- Kind: B2
- Application number: 15/501,507
- Filed: 2015-08-11
- Published: 2017-08-10
- Granted: 2020-09-08
- Earliest claimed: 2014-08-15
- Assignees: ImClone LLC
- Applicants: Imclone, LLC
- Inventors: Paolo B. Abada; Shao-Chun Chang; Yanzhi Hsu; Ling Yang
- Web page: https://patentgrep.com/patent/US10766961B2

## CPC

- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61P 35/00: Antineoplastic agents
- G01N 33/57525: of the liver or pancreas
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- C07K 2317/21: from primates, e.g. man
- G01N 2333/47: Assays involving proteins of known structure or function as defined in the subgroups
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides for a human antibody that binds to human vascular endothelial growth factor receptor 2, preferably ramucirumab, for the treatment of hepatocellular carcinoma (HCC) in patients having levels of alpha-fetoprotein (AFP) of 1.5×ULN (Upper Limit of Normal) or greater, and as a predictive method for the treatment of HCC in patients having AFP levels of 1.5×ULN or greater.

## Claims

### Claim 1

A method of selecting a patient having a hepatocellular tumor and treating said patient with a therapeutically effective amount of ramucirumab, comprising assaying for the level of alpha-fetoprotein in a plasma or serum sample taken from the patient, and selecting and treating the patient with a therapeutically effective amount of ramucirumab if the level of alpha-fetoprotein in the sample is 400 ng/mL or greater.

### Claim 2 (depends on 1)

The method of claim 1, wherein the sample is serum.

### Claim 3 (depends on 1)

The method of claim 1, wherein the sample is plasma.

### Claim 4 (depends on 1)

The method of claim 1, wherein ramucirumab is administered at a dose of about 8 mg/kg, every two weeks.

### Claim 5 (depends on 1)

The method of claim 1, wherein the patient was previously treated with sorafenib.

### Claim 6

A therapeutic regimen for treating a patient with a hepatocellular tumor, comprising: (1) assaying for the level of alpha-fetoprotein in a plasma or serum sample taken from the patient, (2) selecting the patient for treatment with ramucirumab if the level of alpha-fetoprotein in the sample is 400 ng/mL or greater, and (3) administering ramucirumab to the patient if the level of alpha-fetoprotein in the sample is 400-ng/mL or greater.

### Claim 7 (depends on 6)

The method of claim 6, wherein the sample is serum.

### Claim 8 (depends on 6)

The method of claim 6, wherein the sample is plasma.

### Claim 9 (depends on 6)

The method of claim 6, wherein ramucirumab is administered at a dose of about 8 mg/kg, every two weeks.

### Claim 10 (depends on 6)

The method of claim 6, wherein the patient was previously treated with sorafenib.

### Claim 11

A method of treating a hepatocellular tumor in a selected patient, comprising selecting the patient if a serum or plasma sample taken from the patient has an alpha-fetoprotein level of 400 ng/mL or greater, and administering a therapeutically effective amount of ramucirumab to the patient, selected as having a level of alpha-fetoprotein of 400 ng/mL or greater in the serum or plasma sample taken from the patient.

### Claim 12 (depends on 11)

The method of claim 11, wherein the sample is serum.

### Claim 13 (depends on 11)

The method of claim 11, wherein the sample is plasma.

### Claim 14 (depends on 11)

The method of claim 11, wherein the ramucirumab is administered at a dose of about 8 mg/kg, every two weeks.

### Claim 15 (depends on 11)

The method of claim 11, wherein the patient was treated with sorafenib prior to administration of ramucirumab.

### Claim 16

A method of treating a hepatocellular tumor in a selected patient, comprising selecting the patient if a serum or plasma sample taken from the patient has an alpha-fetoprotein level of 400 ng/mL or greater, and administering a therapeutically effective amount of an anti-VEGFR2 antibody to the patient selected as having a level of alpha-fetoprotein of 400 ng/mL or greater in the serum or plasma sample taken from the patient, wherein the anti-VEGFR2 antibody comprises two heavy chains, each with the amino acid sequence of SEQ ID NO: 1, and two light chains, each with the amino acid sequence of SEQ ID NO: 2.

### Claim 17 (depends on 16)

The method of claim 16, wherein the sample is serum.

### Claim 18 (depends on 16)

The method of claim 16, wherein the sample is plasma.

### Claim 19 (depends on 16)

The method of claim 16, wherein the anti-VEGFR2 antibody is administered at a dose of about 8 mg/kg, every two weeks.

### Claim 20 (depends on 16)

The method of claim 16, wherein the patient was previously treated with sorafenib.
